CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+16%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$324M
AUM Growth
+$28.5M
(+9.6%)
Cap. Flow
-$70.4K
Cap. Flow
% of AUM
-0.02%
Top 10 Holdings %
Top 10 Hldgs %
32.96%
Holding
465
New
18
Increased
159
Reduced
244
Closed
13
Top Buys
| 1 |
Vanguard World Funds Extended Duration ETF
EDV
|
$3.28M |
| 2 |
Tesla
TSLA
|
$2.24M |
| 3 |
Apple
AAPL
|
$2.14M |
| 4 |
Meta Platforms (Facebook)
META
|
$2.1M |
| 5 |
Vaxcyte
PCVX
|
$2M |
Top Sells
| 1 |
iQIYI
IQ
|
$4.85M |
| 2 |
Amazon
AMZN
|
$4.7M |
| 3 |
Airbnb
ABNB
|
$3.2M |
| 4 |
Analog Devices
ADI
|
$2.94M |
| 5 |
KE Holdings
BEKE
|
$1.93M |
Sector Composition
| 1 | Technology | 41.8% |
| 2 | Consumer Discretionary | 21.38% |
| 3 | Healthcare | 19.26% |
| 4 | Communication Services | 6.74% |
| 5 | Financials | 4.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Grifois
GRFS
$6.89B
| $13.9K | ﹤0.01% |
1,514
-10
| -0.7% | -$92 |
|
302
Procter & Gamble
PG
$375B
| $13.4K | ﹤0.01% |
88
+48
| +120% | +$7.28K |
|
303
Mirum Pharmaceuticals
MIRM
$3.82B
| $12.9K | ﹤0.01% |
498
-1
| -0.2% | -$26 |
|
304
Crinetics Pharmaceuticals
CRNX
$3.35B
| $12.8K | ﹤0.01% |
708
-23
| -3% | -$414 |
|
305
Adaptive Biotechnologies
ADPT
$1.96B
| $12.7K | ﹤0.01% |
1,891
-49
| -3% | -$329 |
|
306
Diageo
DEO
$61.3B
| $12.3K | ﹤0.01% |
+71
| New | +$12.3K |
|
307
Rhythm Pharmaceuticals
RYTM
$6.78B
| $12.3K | ﹤0.01% |
745
-18
| -2% | -$297 |
|
|
EQRX
308
DELISTED
EQRx, Inc. Common Stock
EQRX
| $11.9K | ﹤0.01% |
6,388
-232
| -4% | -$432 |
|
309
Day One Biopharmaceuticals
DAWN
$773M
| $11.5K | ﹤0.01% |
964
-32
| -3% | -$382 |
|
310
Regenxbio
RGNX
$490M
| $11.4K | ﹤0.01% |
570
-19
| -3% | -$380 |
|
311
Cogent Biosciences
COGT
$1.82B
| $11K | ﹤0.01% |
930
-17
| -2% | -$201 |
|
312
Innoviva
INVA
$1.29B
| $10.9K | ﹤0.01% |
858
-65
| -7% | -$827 |
|
313
ADMA Biologics
ADMA
$4.03B
| $10.7K | ﹤0.01% |
2,913
-80
| -3% | -$295 |
|
314
Lyell Immunopharma
LYEL
$233M
| $10.4K | ﹤0.01% |
164
-5
| -3% | -$317 |
|
315
Avidity Biosciences
RNA
$6.48B
| $10.3K | ﹤0.01% |
928
-31
| -3% | -$344 |
|
316
Phathom Pharmaceuticals
PHAT
$875M
| $10.3K | ﹤0.01% |
717
+153
| +27% | +$2.19K |
|
317
Biomea Fusion
BMEA
$114M
| $10.2K | ﹤0.01% |
464
+66
| +17% | +$1.45K |
|
318
Arcturus Therapeutics
ARCT
$485M
| $9.98K | ﹤0.01% |
348
-12
| -3% | -$344 |
|
319
4D Molecular Therapeutics
FDMT
$340M
| $9.92K | ﹤0.01% |
549
+110
| +25% | +$1.99K |
|
320
Collegium Pharmaceutical
COLL
$1.21B
| $9.76K | ﹤0.01% |
454
-8
| -2% | -$172 |
|
321
Aclaris Therapeutics
ACRS
$227M
| $9.6K | ﹤0.01% |
926
+23
| +3% | +$239 |
|
322
Ardelyx
ARDX
$1.57B
| $9.53K | ﹤0.01% |
2,811
+121
| +4% | +$410 |
|
323
Allogene Therapeutics
ALLO
$255M
| $9.5K | ﹤0.01% |
1,912
-46
| -2% | -$229 |
|
324
Kura Oncology
KURA
$713M
| $9.49K | ﹤0.01% |
897
-31
| -3% | -$328 |
|
325
Galapagos
GLPG
$2.2B
| $9.35K | ﹤0.01% |
230
+48
| +26% | +$1.95K |
|